BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Mill… [+28332 chars]
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of approximatel…
Source:Biomarin.com
Published:
Related News
business
business
business
Japan Government Bond Yields, Stocks Fall After Yen’s Rebound - The Wall Street Journal
The Wall Street Journal•The Wall Street Journal
Samsung Stock Gains as Nvidia AI Chip Supply Nears - TipRanks
South Korean market leader Samsung Electronics ($SSNLF) is set to begin production of its next-generation high-bandwidth memory chips, known as HBM4, as early as next month, according to a Reuters
Tipranks.com•Shalu Saraf
Yen Extends Gains Amid Threat of Intervention: Markets Wrap - Bloomberg.com
The dollar fell against all of its major peers after a rate check Friday by the Federal Reserve Bank of New York spurred speculation the US may assist Japan in efforts to boost the yen. Gold rose above $5,000 for the first time and US stock futures dropped wi…
Bloomberg•Anand Krishnamoorthy, Ruth Carson